Compare Stocks → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:IKTNASDAQ:OKYONASDAQ:PMNNYSEARCA:SBMNASDAQ:VRDN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIKTInhibikase Therapeutics$1.74-8.4%$2.17$0.79▼$4.35$11.28M1.19124,100 shs6,614 shsOKYOOKYO Pharma$1.45+0.2%$1.45$0.92▼$3.25$41.80M0.04151,805 shs622 shsPMNProMIS Neurosciences$1.95$2.04$0.95▼$8.95$36.97M0.6717,088 shs1,430 shsSBMProShares Short Basic Materials$46.38$46.38$42.85▼$55.15$1.86MN/A3,024 shsN/AVRDNViridian Therapeutics$12.79+0.7%$17.29$10.93▼$28.99$802.83M1.07918,253 shs13,906 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIKTInhibikase Therapeutics-0.53%-11.43%-18.78%-37.16%-43.63%OKYOOKYO Pharma+2.84%-1.36%+0.69%-8.81%+14.17%PMNProMIS Neurosciences0.00%-1.02%+0.52%-3.05%-71.28%SBMProShares Short Basic Materials0.00%0.00%0.00%0.00%-0.01%VRDNViridian Therapeutics-2.53%-16.23%-26.89%-36.15%-54.04%Exposed: 10 CENT Crypto to Explode April 20th? (Ad)The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIKTInhibikase Therapeutics1.1126 of 5 stars3.50.00.00.00.01.70.6OKYOOKYO Pharma2.4802 of 5 stars3.55.00.00.00.61.70.6PMNProMIS Neurosciences2.3094 of 5 stars3.54.00.00.01.11.70.6SBMProShares Short Basic MaterialsN/AN/AN/AN/AN/AN/AN/AN/AVRDNViridian Therapeutics1.1376 of 5 stars3.50.00.00.03.30.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIKTInhibikase Therapeutics3.00Buy$27.001,451.72% UpsideOKYOOKYO Pharma3.00Buy$7.00382.76% UpsidePMNProMIS Neurosciences3.00Buy$8.00310.26% UpsideSBMProShares Short Basic Materials0.00N/AN/AN/AVRDNViridian Therapeutics3.00Buy$36.60186.16% UpsideCurrent Analyst RatingsLatest VRDN, PMN, SBM, IKT, and OKYO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/22/2024OKYOOKYO PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$6.00 ➝ $7.003/21/2024VRDNViridian TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$29.00 ➝ $25.003/20/2024VRDNViridian TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.003/5/2024IKTInhibikase TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.002/29/2024VRDNViridian TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$37.002/28/2024VRDNViridian TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.002/28/2024VRDNViridian TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$39.00 ➝ $40.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIKTInhibikase Therapeutics$260K43.37N/AN/A$1.78 per share0.98OKYOOKYO PharmaN/AN/AN/AN/A($0.08) per shareN/APMNProMIS Neurosciences$10K3,697.20N/AN/A$0.20 per share9.75SBMProShares Short Basic MaterialsN/AN/AN/AN/AN/AN/AVRDNViridian Therapeutics$310K2,589.77N/AN/A$4.48 per share2.85Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIKTInhibikase Therapeutics-$19.03M-$3.56N/AN/AN/A-5,886.15%-107.54%-91.82%5/20/2024 (Estimated)OKYOOKYO Pharma-$13.27MN/A0.00N/AN/AN/AN/AN/A8/20/2024 (Estimated)PMNProMIS Neurosciences-$13.21M-$1.13N/AN/AN/AN/AN/A-141.23%5/20/2024 (Estimated)SBMProShares Short Basic MaterialsN/AN/A0.00∞N/AN/AN/AN/AN/AVRDNViridian Therapeutics-$237.73M-$5.32N/AN/AN/A-75,711.48%-121.80%-61.06%5/14/2024 (Estimated)Latest VRDN, PMN, SBM, IKT, and OKYO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024Q4 2023PMNProMIS NeurosciencesN/A-$0.09-$0.09-$0.09N/AN/A3/27/2024Q4 2023IKTInhibikase Therapeutics-$0.78-$0.63+$0.15-$0.63N/AN/A 2/27/2024Q4 2023VRDNViridian Therapeutics-$0.98-$1.35-$0.37-$1.35$0.15 million$0.07 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIKTInhibikase TherapeuticsN/AN/AN/AN/AN/AOKYOOKYO PharmaN/AN/AN/AN/AN/APMNProMIS NeurosciencesN/AN/AN/AN/AN/ASBMProShares Short Basic MaterialsN/AN/AN/AN/AN/AVRDNViridian TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIKTInhibikase TherapeuticsN/A4.134.13OKYOOKYO PharmaN/AN/AN/APMNProMIS NeurosciencesN/A1.461.46SBMProShares Short Basic MaterialsN/AN/AN/AVRDNViridian Therapeutics0.0918.2618.26OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIKTInhibikase Therapeutics3.81%OKYOOKYO Pharma2.97%PMNProMIS Neurosciences50.13%SBMProShares Short Basic MaterialsN/AVRDNViridian TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipIKTInhibikase Therapeutics20.30%OKYOOKYO Pharma40.46%PMNProMIS Neurosciences10.30%SBMProShares Short Basic MaterialsN/AVRDNViridian Therapeutics1.43%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableIKTInhibikase Therapeutics86.48 million5.16 millionNot OptionableOKYOOKYO Pharma828.83 million17.17 millionNot OptionablePMNProMIS Neurosciences618.96 million17.01 millionNot OptionableSBMProShares Short Basic MaterialsN/A40,000N/ANot OptionableVRDNViridian Therapeutics9462.77 million61.87 millionOptionableVRDN, PMN, SBM, IKT, and OKYO HeadlinesSourceHeadlineViridian Therapeutics (NASDAQ:VRDN) Stock Price Down 6.2%marketbeat.com - April 24 at 6:51 PMKnights of Columbus Asset Advisors LLC Boosts Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)marketbeat.com - April 21 at 6:39 AMViridian Therapeutics (NASDAQ:VRDN) Sees Strong Trading Volumeamericanbankingnews.com - April 21 at 2:32 AMViridian Therapeutics (NASDAQ:VRDN) Sees Unusually-High Trading Volumemarketbeat.com - April 19 at 11:58 AMViridian Therapeutics (NASDAQ: VRDN)fool.com - April 13 at 3:28 PMViridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by Vanguard Group Inc.marketbeat.com - April 11 at 4:11 AMViridian Therapeutics (NASDAQ:VRDN) Trading Down 7.5%marketbeat.com - April 10 at 2:51 PMBuy Rating Affirmed for Viridian Therapeutics Amidst TED Treatment Market Potentialmarkets.businessinsider.com - April 6 at 2:51 AMViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com - April 4 at 4:01 PMViridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Rating of "Buy" from Brokeragesmarketbeat.com - April 4 at 2:16 AMViridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by SG Americas Securities LLCmarketbeat.com - April 1 at 4:23 AMVIRIDIAN SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firmprnewswire.com - March 29 at 9:00 AMAnalysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), OmniAb (OABI) and Vericel (VCEL)markets.businessinsider.com - March 25 at 10:01 PMBuy Rating Endorsed for Viridian Therapeutics’ VRDN Treatments Based on Superior Efficacy and Dosing Advantages in TED Marketmarkets.businessinsider.com - March 20 at 8:21 PMUnveiling 4 Analyst Insights On Viridian Therapeuticsmarkets.businessinsider.com - March 20 at 3:20 PMFinding the Next Big Winners: 3 Stocks You Can Snag for Under $20investorplace.com - March 19 at 6:51 PMVRDN Sep 2024 20.000 putfinance.yahoo.com - March 16 at 8:46 AMVRDN Apr 2024 20.000 putfinance.yahoo.com - March 16 at 8:46 AMSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firmstockhouse.com - March 15 at 11:23 PMVRDN Makes Bullish Cross Above Critical Moving Averagenasdaq.com - March 9 at 2:40 PMViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com - March 6 at 4:01 PMViridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conferencefinance.yahoo.com - March 5 at 10:27 AMBuy Rating Affirmed for Viridian Therapeutics Amid Strong Clinical Progress and Market Potentialmarkets.businessinsider.com - March 1 at 8:01 AMBuy Rating on Viridian Therapeutics Backed by Pipeline Progress and Phase 3 Trial Potentialmarkets.businessinsider.com - February 29 at 3:56 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsInhibikase TherapeuticsNYSE:IKTInhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, University of Bordeaux, and Michigan State University, as well as University of California; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.OKYO PharmaNASDAQ:OKYOOKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.ProMIS NeurosciencesNASDAQ:PMNProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.ProShares Short Basic MaterialsNYSEARCA:SBMProShares Short Basic Materials (the Fund) seeks daily investment results that correspond to the inverse (opposite) of the daily performance of Dow Jones U.S. Basic Materials Index (the Index). The Index measures the performance of the basic materials industry of the United States equity market. The Fund invests in derivatives as a substitute for directly shorting stocks in order to gain inverse exposure to the Index. The Fund invests in financial instruments whose value is derived from the value of an underlying asset, interest rate or index. The Fund also invests in short-term cash instruments that have terms to maturity of less than 397 days and exhibit credit profiles. ProShare Advisors LLC is the investment advisor of the Fund.Viridian TherapeuticsNASDAQ:VRDNViridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.